These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30471992)

  • 1. Immunotherapy, Cancer and Rheumatological Diseases: A Review of the Literature and a Series of Cases in a University Hospital.
    Nóvoa Medina FJ; Tejera Segura B; González Rodríguez E; Machín García S; Romero Díaz B; Rodríguez Abreu D
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):413-415. PubMed ID: 30471992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
    Benesova K; Leipe J
    Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatological adverse events secondary to immune checkpoint inhibitors.
    Garbarino MC; Manzano N; Messina O; Zylberman M
    Reumatol Clin (Engl Ed); 2023 Apr; 19(4):215-222. PubMed ID: 37005129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatological Adverse Events Following Immunotherapy for Cancer.
    Cretu I; Cretu B; Cirstoiu C; Cursaru A; Milicescu M; Bojinca M; Ionescu R
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056402
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rheumatological complications of immune checkpoint inhibitor therapy].
    Lazarou I; Fernandez E
    Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
    Ohnuma K; Hatano R; Dang NH; Morimoto C
    Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
    Sebastiani GD; Scirocco C; Galeazzi M
    Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors].
    Zhou J; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhang W; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):671-675. PubMed ID: 31650952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatic immune-related adverse events from cancer immunotherapy.
    Calabrese LH; Calabrese C; Cappelli LC
    Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
    Gediz F; Kobak S
    Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
    Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy, Cancer and Rheumatic Diseases.
    Nóvoa Medina FJ; Rodríguez Abreu D
    Reumatol Clin (Engl Ed); 2019; 15(5):249-251. PubMed ID: 31003829
    [No Abstract]   [Full Text] [Related]  

  • 13. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
    Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic manifestations of malignancy.
    Conaghan PG; Brooks PM
    Curr Opin Rheumatol; 1994 Jan; 6(1):105-10. PubMed ID: 8031673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities from immunotherapy: From clinical trials to real-world clinical practice.
    Riveiro-Barciela M; Trallero-Araguás E; Martínez-Valle F; ;
    Med Clin (Barc); 2020 Dec; 155(12):541-547. PubMed ID: 32868034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital.
    Rasor B; Henderson R; Chan K
    J Oncol Pharm Pract; 2020 Jan; 26(1):60-66. PubMed ID: 30924739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.
    Ezponda Casajús A; Calvo Imirizaldu M; de Torres Tajes JP; García-Baizán A; Castañón Álvarez E; Cano Rafart D; Vivas Pérez I; Bastarrika Alemañ G
    Radiologia (Engl Ed); 2020; 62(2):131-138. PubMed ID: 31405549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].
    Szekanecz É; Szekanecz Z
    Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.